Influence of the route of administration on targeting of ovarian cancer with the chimeric monoclonal antibody MOv18: I.V. Vs. I.P

International Journal of Cancer

Volumn 92, Issue 1, 2001, Pages 106-114

  Van Zanten Przybysz, Iwona ^a   Molthoff, Carla F ^a   Roos, Jan C ^a   Verheijen, René H ^a   Van Hof, Arjan ^a   Buist, Marrije R ^a   Prinssen, Helma M ^a   Hollander, Wim Den ^a   Kenemans, Peter ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Intraperitoneal; Intravenous; Monoclonal antibody; MOv18; Ovarian cancer

Indexed keywords

IODINE 123; IODINE 125; IODINE 131; MONOCLONAL ANTIBODY; MOV 18; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ASCITES; BONE MARROW TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CLEARANCE; DRUG UPTAKE; FEMALE; HUMAN; OVARY CANCER; PRIORITY JOURNAL; RADIOACTIVITY;

EID: 0035314001     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0215(200102)9999:9999<::AID-IJC1145>3.0.CO;2-I     Document Type: Article

References (33)

1. Carcinoma of the ovary
2. Epithelial ovarian cancer
3. Epithelial ovarian cancer: Impact of surgery and chemotherapy on survival during 1977-1990
4. Paclitaxel for platinum-refractory ovarian cancer - Results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103
5. Radioimmunotherapy of ovarian cancer with radiolabelled monoclonal antibodies: Biological basis, present status and future perspectives
6. Antibody-guided irradiation of advanced ovarian cancer with intraperitoneally administered radiolabeled monoclonal antibodies
7. Intraperitoneal radioimmunotherapy of refractory ovarian carcinoma utilizing iodine-131-labeled monoclonal antibody OC125
8. Single-dose intraperitoneal radioimmunotherapy with the murine monoclonal antibody 1-131 MOv18: Clinical results in patients with minimal residual disease of ovarian cancer
9. Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: A phase I/II study
10. Experience with intraperitoneal cisplatin and etoposide and i.v. sodium thiosulphate protection in ovarian cancer patients with either pathologically complete response or minimal residual disease
11. Tissue-level transport mechanisms of intraperitoneally administered monoclonal antibodies
12. Delivery of molecular and cellular medicine to solid tumors
13. Complementation of intracavitary and intravenous administration of a monoclonal antibody (B72.3) in patients with carcinoma
14. Characterization of human ovarian carcinoma associated antigens defined by novel monoclonal antibodies with tumor restricted specificity
15. Folate-binding protein is a marker for ovarian cancer
16. Cloning of a tumor-associated antigen: MOv18 and MOv19 antibodies recognize a folate-binding protein
17. Distribution of OV-TL 3 and MOv18 in normal and malignant ovarian tissue
18. Experimental and clinical analysis of the characteristics of a chimeric monoclonal antibody. MOv18, reactive with an Ovarian cancer-associated antigen
19. 2 fragments in ovarian carcinoma patients
20. Minor human antibody response to a mouse and chimeric monoclonal antibody after a single i.v. infusion in ovarian carcinoma patients: A comparison of five assays
21. Escalating protein doses of chimeric monoclonal antibody MOv18 immunoglobulin G in ovarian carcinoma patients: A phase I study
22. Radioimmunoscintigraphy of ovarian cancer with the MOv18 monoclonal antibody
23. Tumor uptake of intravenously administered radiolabeled antibodies in ovarian carcinoma patients in relation to antigen expression and other tumor characteristics
24. Influence of dose and schedule on the therapeutic efficacy of 1-131 labelled monoclonal antibody 139H2 in a human ovarian cancer xenograft model
25. Chimeric murine human antibodies directed against folate binding receptor are efficient mediators of ovarian carcinoma cell killing
26. Determination of the immunoreactive fraction of radiolabeled monoclonal antibody by linear extrapolation to binding at infinite antigen excess
27. The intraperitoneal delivery of radiolabeled monoclonal antibodies: Studies on the regional delivery advantage
28. Dosimetric analysis of chimeric monoclonal antibody cMOv18 IgG in ovarian carcinoma patients after intraperitoneal and intravenous administration
29. Estimates of radiation absorbed dose for intrapentoneally administered iodine-131 radiolabeled B72.3 monoclonal antibody in patients with peritoneal carcinomatosis
30. Antibody-guided localization of intraperitoneal tumors following intraperitoneal or intravenous antibody administration
31. Intraperitoneal versus intravenous injection of radiolabelled monoclonal antibodies in patients with colorectal carcinoma
32. Distribution and pharmacokinetics of radiolabeled monoclonal antibody OC 125 after intravenous and intraperitoneal administration in gynecologic tumors
33. Advantage of dose fractionation in monoclonal antibody-targeted radioimmunotherapy